Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease

This study aimed to identify preclinical Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) using measurements of both regional cerebral blood flow (rCBF) and cerebrospinal fluid (CSF) biomarkers. Baseline rCBF assessments ((133)Xe method) were performed in 70 patients with MCI who were cognitively stable for 4-6 years, 69 patients with MCI who subsequently developed AD, and 33 healthy individuals. CSF was collected at baseline and analyzed for beta-amyloid(1-42), total tau and phophorylated tau. In contrast to patients with stable MCI, those who subsequently developed AD had decreased rCBF in the temporo-parietal cortex already at baseline. The relative risk of future progression to AD was particularly increased in MCI patients with decreased rCBF in parietal cortex (hazard ratio 3.1, P<0.0001). Subjects with pathological levels of both CSF tau and beta-amyloid(1-42) were also at high risk of developing AD (hazard ratio 13.4, P<0.0001). The MCI patients with a combination of decreased parietal rCBF and pathological CSF biomarkers at baseline had a substantially increased risk of future development of AD, with a hazard ratio of 24.3 (P<0.0001), when compared to those with normal CSF biomarkers. Moreover, decreased parietal rCBF (but not CSF biomarkers) was associated with a more rapid progression to AD. In conclusion, the combination of rCBF and CSF biomarkers improves the risk assessment of progression to AD in patients with MCI.

[1]  J. Growdon,et al.  Biomarkers and surrogates , 2004, NeuroRX.

[2]  A. Drzezga,et al.  Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  Nick C Fox,et al.  New developments in mild cognitive impairment and Alzheimer's disease , 2006, Current opinion in neurology.

[4]  Hiroshi Matsuda,et al.  The prediction of rapid conversion to Alzheimer's disease in mild cognitive impairment using regional cerebral blood flow SPECT , 2005, NeuroImage.

[5]  K. Blennow,et al.  CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.

[6]  Masatoshi Itoh,et al.  Combined Analysis of CSF Tau Levels and [(123)I]Iodoamphetamine SPECT in Mild Cognitive Impairment: Implications for a Novel Predictor of Alzheimer's Disease. , 2002, The American journal of psychiatry.

[7]  D. Perani,et al.  Pre–clinical diagnosis of Alzheimer disease combining platelet amyloid precursor protein ratio and rCBF spect analysis , 2005, Journal of Neurology.

[8]  R. Michels,et al.  Diagnostic and Statistical Manual of Mental Disorders, 3rd ed , 1981 .

[9]  A. Barabash,et al.  Regional cerebral blood flow assessed with 99mTc-ECD SPET as a marker of progression of mild cognitive impairment to Alzheimer's disease , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  G. Alexander,et al.  Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.

[11]  B L Holman,et al.  Preclinical prediction of Alzheimer's disease using SPECT , 1998, Neurology.

[12]  T. Ohnishi,et al.  Longitudinal Evaluation of Early Alzheimer's Disease Using Brain Perfusion Spect the Recruitment Was For , 2000 .

[13]  D. Bennett,et al.  Vitamin E and donepezil for the treatment of mild cognitive impairment. , 2005, The New England journal of medicine.

[14]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[15]  Ove Almkvist,et al.  Voxel- and VOI-based analysis of SPECT CBF in relation to clinical and psychological heterogeneity of mild cognitive impairment , 2003, NeuroImage.

[16]  M. Chong,et al.  Preclinical Alzheimer's disease: diagnosis and prediction of progression , 2005, The Lancet Neurology.

[17]  W. Obrist,et al.  Regional cerebral blood flow estimated by 133-xenon inhalation. , 1975, Stroke.

[18]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[19]  Lars-Olof Wahlund,et al.  Cingulate cortex hypoperfusion predicts Alzheimer's disease in mild cognitive impairment , 2002, BMC neurology.

[20]  B. Dubois,et al.  Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization , 2003, Neurology.

[21]  J. Risberg,et al.  Regional cerebral blood flow measurements in the clinical evaluation of demented patients. , 1997, Dementia and geriatric cognitive disorders.

[22]  H. Möller,et al.  Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment , 2004, Molecular Psychiatry.

[23]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[24]  L. Thal,et al.  A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment , 2005, Neuropsychopharmacology.

[25]  David Eidelberg,et al.  Imaging markers of mild cognitive impairment: Multivariate analysis of CBF SPECT , 2007, Neurobiology of Aging.

[26]  H. Möller,et al.  Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. , 2004, Molecular psychiatry.

[27]  J. Risberg.  Regional cerebral blood flow measurements by 133Xe-inhalation: Methodology and applications in neuropsychology and psychiatry , 1980, Brain and Language.

[28]  Anders Wallin,et al.  Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. , 2005, Clinical chemistry.

[29]  D. Anchisi,et al.  Combined 99mTc-ECD SPECT and neuropsychological studies in MCI for the assessment of conversion to AD , 2006, Neurobiology of Aging.

[30]  Bradford C. Dickerson,et al.  Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer’s disease , 2005, NeuroRX.

[31]  D. Perani,et al.  MCI conversion to dementia and the APOE genotype , 2004, Neurology.

[32]  K. Blennow,et al.  Longitudinal stability of CSF biomarkers in Alzheimer's disease , 2007, Neuroscience Letters.

[33]  R. Petersen.  Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[34]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[35]  J. Baron,et al.  FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment , 2005, Neurocase.

[36]  J. Hanley,et al.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases. , 1983, Radiology.

[37]  O Almkvist,et al.  Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment , 2001, Neuroreport.

[38]  R. Petersen,et al.  Mild cognitive impairment , 2006, The Lancet.